We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

CEPHEID

Develops, manufactures, and markets molecular systems and tests for institutions to perform sophisticated genetic tes... read more Featured Products: More products

Download Mobile App




First POC Hepatitis C RNA Test Enables Single-Visit Testing and Treatment

By LabMedica International staff writers
Posted on 28 Jun 2024
Print article
Image: The U.S. FDA has granted marketing authorization for the Xpert HCV test together with the GeneXpert Xpress System (Photo courtesy of Cepheid)
Image: The U.S. FDA has granted marketing authorization for the Xpert HCV test together with the GeneXpert Xpress System (Photo courtesy of Cepheid)

Hepatitis C, a liver infection caused by the hepatitis C virus (HCV), spreads through contact with the blood of an infected person. While some individuals may experience a short-term illness, over half of those infected develop a chronic, long-term condition. In the United States, it is estimated that between 2.4 and 4 million people are living with hepatitis C. If untreated, the virus can lead to severe health issues, including liver cancer and liver failure. Until now, HCV testing has involved multiple steps, requiring patients to return for results and further tests, often resulting in missed diagnoses and treatment. Now, a breakthrough has been made with the introduction of the first point-of-care HCV test, which facilitates testing and treatment in a single visit for those at risk.

Developed by Cepheid (Sunnyvale, CA, USA), the Xpert HCV test eliminates the need to send samples to a central lab and can detect HCV RNA from a fingertip blood sample, delivering results within approximately one hour. The U.S. Food and Drug Administration has granted marketing authorization for the use of the Xpert HCV test alongside the GeneXpert Xpress System. This test is authorized for use in various settings under a CLIA (Clinical Laboratory Improvement Amendments) Certificate of Waiver, including substance use disorder treatment centers, correctional facilities, syringe service programs, physician's offices, emergency departments, and urgent care clinics. This significant development supports a test-and-treat approach, allowing individuals to be tested and, if they test positive for HCV RNA, to be connected to care and potentially begin treatment during the same healthcare visit.

"Despite the existence of a safe and highly effective oral cure for hepatitis C, many people do not know they have the disease due partly to the lack of availability of convenient, widespread testing options," said Jeff Shuren, M.D., J.D., director of the FDA's Center for Devices and Radiological Health. "Equipping health care providers with tools to diagnose and treat patients in the same visit can result in hundreds of thousands more hepatitis C patients being diagnosed and treated, preventing individual disease progression and additional spread of the virus."

New
Gold Member
Pharmacogenetics Panel
VeriDose Core Panel v2.0
Automated Blood Typing System
IH-500 NEXT
New
Lab Sample Rotator
H5600 Revolver
New
Newborn Screening Test
NeoMass AAAC 3.0

Print article

Channels

Clinical Chemistry

view channel
Image: Rapid and non-invasive analysis of paracetamol overdose using paper arrow-mass spectrometry (Photo courtesy of Dr Simon Maher/University of Liverpool)

New Saliva Test Rapidly Identifies Paracetamol Overdose

Paracetamol is the most widely used medication worldwide, and its easy availability contributes to its frequent misuse and overdose. Overdosing on paracetamol can lead to liver toxicity, requiring hospitalization.... Read more

Hematology

view channel
Image: RHD screening just got easier with single exon NIPT testing (Photo courtesy of Devyser)

Non-Invasive Test Solution Determines Fetal RhD Status from Maternal Plasma

RhD (rhesus D) is a blood group type that can trigger immune responses. Individuals who lack RhD on their red blood cells are classified as RhD-negative. These individuals may produce antibodies against... Read more

Immunology

view channel
Image: Concept for the device. Memory B cells able to bind influenza virus remain stuck to channels despite shear forces (Photo courtesy of Steven George/UC Davis)

Microfluidic Chip-Based Device to Measure Viral Immunity

Each winter, a new variant of influenza emerges, posing a challenge for immunity. People who have previously been infected or vaccinated against the flu may have some level of protection, but how well... Read more

Microbiology

view channel
Image: A new test finds bacteria in liquids and indicate their presence by changing color (Photo courtesy of Georgia Kirkos/McMaster University)

New Hands-Free Rapid Test Detects Bacteria in Fluids

Bacteriophages, the most abundant form of life on Earth, are specialized to target and destroy specific types of bacteria. Their natural ability to fight bacteria has long been harnessed to treat infections.... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.